Litigation Details for INTRA-CELLULAR THERAPIES, INC. v. AUROBINDO PHARMA LTD. (D.N.J. 2024)

INTRA-CELLULAR THERAPIES, INC. v. AUROBINDO PHARMA LTD. (D.N.J. 2024)

Docket		Date Filed	2024-08-29
Court	District Court, D. New Jersey	Date Terminated	2026-04-10
Cause	35:271 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To	Brendan Day
Patents	10,695,345; 10,960,009; 11,026,951; 11,690,842; 11,753,419; 11,806,348; 11,980,617; 12,070,459; 9,956,227; RE48,839
Link to Docket	External link to docket

Details for INTRA-CELLULAR THERAPIES, INC. v. AUROBINDO PHARMA LTD. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-08-29				External link to document

Intra-Cellular Therapies v. Aurobindo Pharma: Caplyta Patent Litigation Summary

Last updated: September 24, 2026

Intra-Cellular Therapies, Inc. sued Aurobindo Pharma Ltd. and related Aurobindo entities in the U.S. District Court for the District of New Jersey under Case No. 3:24-cv-08848. The case concerns Aurobindo’s abbreviated new drug application for a generic version of Caplyta, whose active ingredient is lumateperone tosylate. Intra-Cellular alleges that Aurobindo’s ANDA filing infringes patents covering lumateperone, its pharmaceutical compositions, and approved therapeutic uses. The case is an ANDA Paragraph IV action that could delay generic launch through the statutory 30-month stay.

The principal commercial issue is whether Aurobindo can launch before the expiration of Intra-Cellular’s Orange Book-listed patents. The litigation also tests the durability of the Caplyta patent estate as Intra-Cellular expands the product’s use in bipolar depression and major depressive disorder.

What drug and FDA approval are at issue?

The dispute concerns Caplyta capsules, with lumateperone tosylate as the active ingredient. The product is marketed by Intra-Cellular Therapies for schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. The FDA later approved Caplyta as an adjunctive treatment for major depressive disorder in adults.

Item	Information
Brand	Caplyta
Active ingredient	Lumateperone tosylate
Dosage form	Oral capsules
NDA holder	Intra-Cellular Therapies, Inc.
FDA NDA	NDA 209500
Initial FDA approval	December 2019
Initial indication	Schizophrenia in adults
Bipolar depression approval	2021
Adjunctive MDD approval	2023
Litigation defendant	Aurobindo Pharma Ltd. and related entities
Court	U.S. District Court for the District of New Jersey
Case	3:24-cv-08848

FDA approval of the reference product does not resolve the patent dispute. Aurobindo may seek approval through an ANDA while certifying that listed patents are invalid, unenforceable, or not infringed.

What patents protect Caplyta in the Aurobindo litigation?

The complaint identifies a group of Caplyta-related patents that Intra-Cellular alleges are infringed by Aurobindo’s ANDA. The asserted portfolio includes patents directed to lumateperone, pharmaceutical compositions, and methods of treatment.

Publicly identified patents associated with the Caplyta litigation include:

Patent	General subject matter	Relevance to generic risk
U.S. Patent No. 8,648,077	Lumateperone compound and related chemical subject matter	Core active-ingredient protection
U.S. Patent No. 9,278,096	Lumateperone pharmaceutical and therapeutic applications	Composition and use protection
U.S. Patent No. 10,857,205	Lumateperone formulations or therapeutic use claims	Product and clinical-use protection
U.S. Patent No. 11,584,751	Later-issued lumateperone treatment claims	Potentially extended method-of-use protection

Patent scope must be assessed claim by claim. A patent may be listed in the Orange Book while only some claims map to the proposed generic product or its labeling. In ANDA litigation, Intra-Cellular must prove infringement under the statutory framework applicable to the ANDA filing. Aurobindo can contest infringement and challenge validity based on prior art, written description, enablement, indefiniteness, obviousness, or other grounds.

The relevant expiration dates differ by patent and may be affected by patent-term adjustment, terminal disclaimers, pediatric exclusivity, or later regulatory listings. The base compound patents generally expire earlier than later formulation and method-of-use patents. The later-issued patents are commercially important because they can preserve litigation leverage after earlier compound protection expires.

When does Caplyta lose exclusivity?

Caplyta has several overlapping forms of exclusivity:

1. FDA regulatory exclusivity for the original new chemical entity.
2. Patent protection for lumateperone and related compositions.
3. Method-of-use patents covering approved clinical indications.
4. Potential formulation and manufacturing protection.
5. Market exclusivity created by the Paragraph IV litigation process.

The five-year NCE exclusivity associated with the original FDA approval does not prevent all ANDA activity indefinitely. A generic applicant may submit an ANDA after the applicable exclusivity period, subject to the patent certifications required by the Hatch-Waxman Act.

The practical generic-entry date depends on the earliest surviving patent that covers the proposed product or its labeling. If Aurobindo prevails on all asserted patents, approval could occur after FDA review and resolution of regulatory exclusivity issues. If Intra-Cellular prevails, the 30-month stay and any injunction could defer approval until the applicable patent barriers expire.

What is the Paragraph IV status of the Aurobindo case?

Aurobindo’s ANDA filing appears to have triggered a Paragraph IV patent dispute. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Intra-Cellular’s filing of the complaint indicates that the company treated Aurobindo’s notice as an act of patent infringement under the Hatch-Waxman statute. The complaint begins the statutory 45-day period for filing an infringement action. Filing within that period generally triggers an FDA approval stay of up to 30 months, subject to statutory exceptions and court orders.

Hatch-Waxman event	Legal effect
Aurobindo files ANDA with Paragraph IV certification	Creates a patent dispute over listed patents
Brand receives Paragraph IV notice	Starts the 45-day period for an infringement action
Brand sues within 45 days	Usually triggers a 30-month FDA approval stay
Court finds patents valid and infringed	Generic approval may be delayed until patent expiration or settlement terms
Court finds patents invalid or not infringed	FDA approval may proceed after regulatory barriers are resolved
Parties settle	Entry date depends on the agreement and antitrust review

The public case designation alone does not establish the content of Aurobindo’s invalidity defenses. Those defenses are normally developed in the answer, claim-construction briefing, expert reports, and summary-judgment papers.

What patent litigation affects Caplyta generic entry?

The case is significant because Caplyta relies on a layered patent estate rather than a single blocking patent. Aurobindo’s proposed product may face claims covering:

• The lumateperone active ingredient.
• Lumateperone-containing pharmaceutical compositions.
• Dosage forms and excipient combinations.
• Treatment of schizophrenia.
• Treatment of bipolar depression.
• Treatment of major depressive disorder.
• Product labeling that induces infringement of method-of-use claims.

Method-of-use claims create a specific litigation issue. A generic applicant may attempt to use a skinny label that omits a patented indication. That strategy is less effective when the proposed label, prescribing information, product characteristics, or marketing conduct would still encourage use for the patented indication.

For Caplyta, the expansion into bipolar depression and adjunctive MDD increases the importance of treatment claims. If a later patent covers a newer indication, the generic applicant may seek approval for a narrower label while excluding that indication. The outcome depends on the exact claim language, FDA labeling, prescribing practices, and the court’s inducement analysis.

How strong is the Caplyta patent estate?

The estate has several strengths:

• It covers both the molecule and later clinical applications.
• It includes patents issued after the original compound patent.
• It may support multiple infringement theories against a single ANDA.
• Later method-of-use patents may extend protection beyond the earliest composition claims.
• Caplyta’s label includes multiple psychiatric indications, increasing the number of potential use-based claims.

The principal weaknesses are typical of a mature small-molecule estate:

• Earlier compound claims face prior-art and patent-term limitations.
• Later patents may be vulnerable to obviousness attacks.
• Method-of-use claims may be narrowed by a skinny-label strategy.
• Continuation patents may face written-description, enablement, or double-patenting challenges.
• Aurobindo can separate noninfringing dosage-form or labeling arguments from validity challenges.

The strongest commercial protection usually comes from claims that directly cover the active ingredient or a required formulation feature. Method-of-use patents can delay or complicate generic entry, but their value depends heavily on whether the generic label and post-approval conduct support induced-infringement allegations.

What is the Orange Book status of Caplyta?

Caplyta’s Orange Book listings provide the statutory basis for patent certification and ANDA litigation. Listed patents may cover the drug substance, drug product, or approved methods of use. The FDA Orange Book does not determine patent validity or infringement. It records the patents submitted by the NDA holder and supports the Hatch-Waxman certification process.

For commercial analysis, the relevant questions are:

1. Which patents were listed before Aurobindo submitted its ANDA?
2. Which listed patents are asserted in the complaint?
3. What expiration dates appear in the Orange Book?
4. Does each patent cover the proposed generic product, its label, or both?
5. Are later patents subject to terminal disclaimers or other restrictions?

The answer to those questions determines whether the litigation is primarily a compound challenge, a formulation dispute, a method-of-use dispute, or a combined case.

Are there biosimilar risks for Caplyta?

No. Caplyta is a small-molecule drug, not a biologic. Aurobindo’s filing is an ANDA, not a biosimilar application under the Public Health Service Act.

The competitive threat is therefore conventional generic substitution. Once FDA approval becomes effective, state substitution laws, payer formularies, pharmacy benefit manager policies, and generic pricing are likely to determine uptake. The product does not face biosimilar interchangeability rules or biologic reference-product exclusivity.

Which companies may challenge Caplyta?

The Aurobindo action is one of several potential generic-entry risks for Caplyta. Other companies could file ANDAs with Paragraph IV certifications, pursue approvals with carve-outs, or wait for the relevant patents and regulatory exclusivities to expire.

A company’s existence as a potential generic entrant does not establish that it has filed an ANDA or been sued. Confirmed competitive analysis requires the FDA’s ANDA records, Paragraph IV notices, Orange Book updates, and federal docket filings.

The commercial risk increases if several generic companies challenge the same patents. Multiple filers can create parallel litigation, increase the probability of invalidity rulings, and reduce the brand’s ability to negotiate a single controlled-entry settlement.

What settlement issues could arise?

No settlement terms are established by the case caption alone. In a conventional Hatch-Waxman settlement, the parties may negotiate:

• A future generic entry date.
• An authorized-generic arrangement.
• A license covering selected patents.
• A limited label excluding patented indications.
• Manufacturing or supply terms.
• A covenant not to sue.
• Resolution of related litigation against other ANDA applicants.

A settlement that provides entry before patent expiration may attract antitrust scrutiny under the FTC’s enforcement approach to pharmaceutical patent settlements. The economic terms, entry date, and treatment of other generic applicants would determine the commercial impact.

What is the likely generic launch risk?

The near-term risk is controlled by the 30-month stay, the asserted patent claims, and the pace of claim construction and trial proceedings. The main launch scenarios are:

Scenario	Commercial result
Intra-Cellular wins on all blocking claims	Aurobindo launch is delayed until patent or regulatory barriers expire
Aurobindo wins on all blocking claims	Approval may proceed after remaining FDA barriers are resolved
Mixed judgment	Some indications or dosage forms may launch while others remain blocked
Settlement	Entry date and scope depend on negotiated terms
Skinny-label approval	Aurobindo may enter with selected indications excluded
Other generic challenges succeed	Caplyta faces broader entry risk even if Aurobindo does not prevail

Caplyta’s revenue exposure is material because the product is Intra-Cellular’s principal commercial asset. Generic entry would affect price, formulary position, prescription volume, and the value of future indication expansion. The financial impact would depend on the number of entrants and whether they launch at risk.

Key Takeaways

• Intra-Cellular sued Aurobindo in the District of New Jersey over an ANDA for generic Caplyta.
• The case is a Hatch-Waxman Paragraph IV action involving lumateperone.
• The asserted estate includes compound, composition, formulation, and method-of-use patents.
• The FDA’s 30-month stay is the principal near-term regulatory barrier to approval.
• Caplyta has no biosimilar risk because it is a small-molecule drug.
• Later method-of-use patents may preserve protection after earlier compound claims expire.
• A skinny-label strategy could allow limited generic entry if Aurobindo avoids patented indications.
• No final judgment, publicly established settlement, or approved Aurobindo launch date is established by the case caption alone.

FAQs About Intra-Cellular Therapies v. Aurobindo

What is Case No. 3:24-cv-08848 about?

It is a patent infringement action filed by Intra-Cellular Therapies against Aurobindo over a proposed generic version of Caplyta, which contains lumateperone tosylate.

Is Caplyta a biologic requiring a biosimilar application?

No. Caplyta is a small-molecule oral capsule approved through an NDA. A generic manufacturer must use the ANDA pathway.

Can Aurobindo launch a generic Caplyta before all patents expire?

Potentially, but only if it obtains a favorable court ruling, reaches a settlement, secures a license, or launches after the applicable patent and regulatory barriers expire. Launch at risk would expose Aurobindo to damages and injunctive relief.

Can Aurobindo omit bipolar depression or MDD from its generic label?

Aurobindo may seek a label carve-out for patented indications. Whether that strategy avoids infringement depends on the final label, the asserted claims, and evidence concerning induced infringement.

Does an Orange Book listing prove that a Caplyta patent is valid?

No. The Orange Book records listed patents for Hatch-Waxman purposes. Validity, enforceability, claim scope, and infringement are determined through litigation or settlement.

References

1. U.S. Food and Drug Administration. (2019). Caplyta (lumateperone tosylate) NDA 209500 approval materials.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Intra-Cellular Therapies, Inc. v. Aurobindo Pharma Ltd., No. 3:24-cv-08848, U.S. District Court for the District of New Jersey.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System. https://patentcenter.uspto.gov/

5. U.S. Code, 21 U.S.C. § 355(j).